Company intelligence / Profile preview

REMD (睿刀医疗)

China

Ownership: Private
Development stage: Other

Overview

REMD's REMD-G1 is the world's first approved device for treating prostate cancer using irreversible electroporation, already commercialized and used in hospitals. Its REMD-G5 device for cardiac pulsed field ablation has entered the China NMPA special approval pathway for innovative medical devices (2022).

Therapeutic areas: CardiovascularOncologyMen's Health
Modalities: DeviceIrreversible electroporation therapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on REMD (睿刀医疗).

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REMD (睿刀医疗).

Explore the full profile